David Gardiner

Summary

Affiliation: Bristol-Myers Squibb
Country: USA

Publications

  1. pmc A randomized, double-blind, placebo-controlled assessment of BMS-936558, a fully human monoclonal antibody to programmed death-1 (PD-1), in patients with chronic hepatitis C virus infection
    David Gardiner
    Bristol Myers Squibb, Pennington, New Jersey, USA
    PLoS ONE 8:e63818. 2013
  2. pmc A randomized trial of tigecycline versus ampicillin-sulbactam or amoxicillin-clavulanate for the treatment of complicated skin and skin structure infections
    Peter Matthews
    Department of Family Medicine, Department of Health, Mpumalanga, Middelburg, 1050, South Africa
    BMC Infect Dis 12:297. 2012
  3. pmc Switch therapy in hospitalized patients with community-acquired pneumonia: tigecycline vs. levofloxacin
    Julio A Ramirez
    University of Louisville, Louisville, KY 40202, USA
    BMC Infect Dis 12:159. 2012
  4. doi request reprint Resistance analysis of hepatitis C virus genotype 1 prior treatment null responders receiving daclatasvir and asunaprevir
    Fiona McPhee
    Research and Development, Bristol Myers Squibb, Wallingford, CT, USA
    Hepatology 58:902-11. 2013

Collaborators

  • Kyong Mi Chang
  • Eric Lawitz
  • K Rajender Reddy
  • Dennis Hernandez
  • Fiona McPhee
  • Timothy Babinchak
  • Julio A Ramirez
  • Peter Matthews
  • Robert Fridell
  • Timothy Eley
  • Joseph Ueland
  • Arlene Carifa
  • Fei Yu
  • Paul Falk
  • Chunfu Wang
  • Aaron Monikowski
  • Nannan Zhou
  • Denise Rill
  • Ron Pedersen
  • Marc Alpert
  • Paul C McGovern
  • Angel C Cooper
  • Timothy Wiemken
  • Edward Zito
  • Galia Rahav

Detail Information

Publications4

  1. pmc A randomized, double-blind, placebo-controlled assessment of BMS-936558, a fully human monoclonal antibody to programmed death-1 (PD-1), in patients with chronic hepatitis C virus infection
    David Gardiner
    Bristol Myers Squibb, Pennington, New Jersey, USA
    PLoS ONE 8:e63818. 2013
    ..Further investigation of PD-1 pathway blockade in chronic viral disease is warranted...
  2. pmc A randomized trial of tigecycline versus ampicillin-sulbactam or amoxicillin-clavulanate for the treatment of complicated skin and skin structure infections
    Peter Matthews
    Department of Family Medicine, Department of Health, Mpumalanga, Middelburg, 1050, South Africa
    BMC Infect Dis 12:297. 2012
    ..Complicated skin and skin structure infections (cSSSIs) frequently result in hospitalization with significant morbidity and mortality...
  3. pmc Switch therapy in hospitalized patients with community-acquired pneumonia: tigecycline vs. levofloxacin
    Julio A Ramirez
    University of Louisville, Louisville, KY 40202, USA
    BMC Infect Dis 12:159. 2012
    ..This analysis compares switch therapy using tigecycline versus levofloxacin in hospitalized patients with community-acquired pneumonia (CAP)...
  4. doi request reprint Resistance analysis of hepatitis C virus genotype 1 prior treatment null responders receiving daclatasvir and asunaprevir
    Fiona McPhee
    Research and Development, Bristol Myers Squibb, Wallingford, CT, USA
    Hepatology 58:902-11. 2013
    ..NS5A resistance variants persisted while NS3 resistance variants generally decayed, suggesting a higher relative fitness of NS5A variants...